• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Is awareness of chronic kidney disease associated with evidence-based guideline-concordant outcomes?慢性肾脏病意识与基于循证指南一致的结局相关吗?
Am J Nephrol. 2012;35(2):191-7. doi: 10.1159/000335935. Epub 2012 Jan 27.
2
Healthy behaviors, risk factor control and awareness of chronic kidney disease.健康行为、危险因素控制与慢性肾脏病知晓率。
Am J Nephrol. 2013;37(2):135-43. doi: 10.1159/000346712. Epub 2013 Jan 31.
3
A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂对糖尿病患者终末期肾病和主要不良心血管事件影响的比较:台湾一项基于人群的动态队列研究
Cardiovasc Diabetol. 2016 Apr 2;15:56. doi: 10.1186/s12933-016-0365-x.
4
Aldosterone antagonists for preventing the progression of chronic kidney disease.用于预防慢性肾脏病进展的醛固酮拮抗剂。
Cochrane Database Syst Rev. 2014 Apr 29(4):CD007004. doi: 10.1002/14651858.CD007004.pub3.
5
Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?慢性肾脏病进展是否受肾素-血管紧张素系统阻滞剂类型的影响?
Nephron. 2019;143(2):100-107. doi: 10.1159/000500925. Epub 2019 Jun 14.
6
Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.肾素-血管紧张素系统抑制剂与钙通道阻滞剂联合应用对高血压合并慢性肾脏病患者的肾脏保护作用
Chin Med J (Engl). 2016 Mar 5;129(5):562-9. doi: 10.4103/0366-6999.176987.
7
Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study.蛋白尿性慢性肾脏病中血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的应用障碍:一项观察性研究。
Mayo Clin Proc. 2021 Aug;96(8):2114-2122. doi: 10.1016/j.mayocp.2020.12.038. Epub 2021 May 2.
8
Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂单药治疗可延缓台湾地区慢性肾脏病患者肾功能恶化。
Sci Rep. 2019 Feb 25;9(1):2694. doi: 10.1038/s41598-019-38991-z.
9
Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States.美国肾功能受损人群中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂使用趋势。
J Am Soc Nephrol. 2019 Jul;30(7):1314-1321. doi: 10.1681/ASN.2018100971. Epub 2019 Jun 5.
10
CKD Awareness Among US Adults by Future Risk of Kidney Failure.未来发生肾衰竭风险对美国成年人慢性肾脏病知晓率的影响。
Am J Kidney Dis. 2020 Aug;76(2):174-183. doi: 10.1053/j.ajkd.2020.01.007. Epub 2020 Apr 15.

引用本文的文献

1
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.克服实施慢性肾脏病新指南导向治疗的障碍。
Nephrol Dial Transplant. 2023 Feb 28;38(3):532-541. doi: 10.1093/ndt/gfac283.
2
Patient Awareness of CKD: A Systematic Review and Meta-analysis of Patient-Oriented Questions and Study Setting.慢性肾脏病患者的知晓情况:针对患者导向性问题及研究背景的系统评价与荟萃分析
Kidney Med. 2021 Jun 1;3(4):576-585.e1. doi: 10.1016/j.xkme.2021.03.014. eCollection 2021 Jul-Aug.
3
Medical Nutrition Therapy Access in CKD: A Cross-sectional Survey of Patients and Providers.慢性肾脏病患者的医学营养治疗可及性:一项针对患者及医疗服务提供者的横断面调查
Kidney Med. 2020 Nov 11;3(1):31-41.e1. doi: 10.1016/j.xkme.2020.09.005. eCollection 2021 Jan-Feb.
4
CKD Awareness in the General Population: Performance of CKD-Specific Questions.普通人群对慢性肾脏病的认知:慢性肾脏病特定问题的表现
Kidney Med. 2019 Feb 25;1(2):43-50. doi: 10.1016/j.xkme.2019.01.005. eCollection 2019 Mar-Apr.
5
Electronic Decision Support for Management of CKD in Primary Care: A Pragmatic Randomized Trial.电子决策支持在初级保健中管理 CKD:一项实用随机试验。
Am J Kidney Dis. 2020 Nov;76(5):636-644. doi: 10.1053/j.ajkd.2020.05.013. Epub 2020 Jul 22.
6
Chronic Kidney Disease Awareness and Longitudinal Health Outcomes: Results from the REasons for Geographic And Racial Differences in Stroke Study.慢性肾脏病认知与纵向健康结局:来自 REasons for Geographic And Racial Differences in Stroke Study 的结果。
Am J Nephrol. 2020;51(6):463-472. doi: 10.1159/000507774. Epub 2020 Apr 29.
7
CKD Awareness Among US Adults by Future Risk of Kidney Failure.未来发生肾衰竭风险对美国成年人慢性肾脏病知晓率的影响。
Am J Kidney Dis. 2020 Aug;76(2):174-183. doi: 10.1053/j.ajkd.2020.01.007. Epub 2020 Apr 15.
8
Translating CKD Research into Primary Care Practice: a Group-Randomized Study.将慢性肾脏病研究转化为基层医疗实践:一项群组随机研究。
J Gen Intern Med. 2020 May;35(5):1435-1443. doi: 10.1007/s11606-019-05353-4. Epub 2019 Dec 10.
9
Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011-2016.2011 - 2016年美国慢性肾病成人患者使用潜在肾毒性药物情况:美国国家健康与营养检查调查(NHANES)
J Gen Intern Med. 2020 Apr;35(4):1092-1101. doi: 10.1007/s11606-019-05557-8. Epub 2019 Dec 2.
10
Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial.美国公共保障医疗服务系统中基于初级保健的慢性肾脏病登记研究:一项实用随机试验
Am J Kidney Dis. 2018 Aug;72(2):168-177. doi: 10.1053/j.ajkd.2018.01.058. Epub 2018 Apr 23.

本文引用的文献

1
Development and results of a kidney disease knowledge survey given to patients with CKD.向 CKD 患者发放的肾脏病知识调查问卷的编制与结果。
Am J Kidney Dis. 2011 Mar;57(3):387-95. doi: 10.1053/j.ajkd.2010.09.018. Epub 2010 Dec 18.
2
CKD awareness and blood pressure control in the primary care hypertensive population.在基层医疗机构的高血压患者中提高对慢性肾脏病的认识和血压控制水平。
Am J Kidney Dis. 2011 Jan;57(1):71-7. doi: 10.1053/j.ajkd.2010.08.022. Epub 2010 Nov 17.
3
Primary care management of chronic kidney disease.慢性肾脏病的初级保健管理。
J Gen Intern Med. 2011 Apr;26(4):386-92. doi: 10.1007/s11606-010-1523-6. Epub 2010 Oct 5.
4
Intensive blood-pressure control in hypertensive chronic kidney disease.高血压性慢性肾脏病的强化血压控制。
N Engl J Med. 2010 Sep 2;363(10):918-29. doi: 10.1056/NEJMoa0910975.
5
A new equation to estimate glomerular filtration rate.一种估算肾小球滤过率的新公式。
Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
6
2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.2009年重点更新内容纳入《美国心脏病学会/美国心脏协会2005年成人心力衰竭诊断与管理指南》:美国心脏病学基金会/美国心脏协会实践指南工作组与国际心肺移植学会合作制定的报告
J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90. doi: 10.1016/j.jacc.2008.11.013.
7
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).糖尿病与慢性肾脏病认知:肾脏早期评估项目(KEEP)与国家健康和营养检查调查(NHANES)
Am J Kidney Dis. 2009 Apr;53(4 Suppl 4):S11-21. doi: 10.1053/j.ajkd.2009.01.004.
8
Prevalence and awareness of CKD among African Americans: the Jackson Heart Study.非裔美国人中慢性肾脏病的患病率及知晓率:杰克逊心脏研究
Am J Kidney Dis. 2009 Feb;53(2):238-47. doi: 10.1053/j.ajkd.2008.08.035.
9
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.强化血糖控制与心血管事件预防:ACCORD、ADVANCE及退伍军人事务部糖尿病试验的启示:美国糖尿病协会立场声明及美国心脏病学会基金会和美国心脏协会科学声明
Circulation. 2009 Jan 20;119(2):351-7. doi: 10.1161/CIRCULATIONAHA.108.191305. Epub 2008 Dec 17.
10
Patient awareness of chronic kidney disease: trends and predictors.慢性肾脏病患者的知晓情况:趋势与预测因素
Arch Intern Med. 2008 Nov 10;168(20):2268-75. doi: 10.1001/archinte.168.20.2268.

慢性肾脏病意识与基于循证指南一致的结局相关吗?

Is awareness of chronic kidney disease associated with evidence-based guideline-concordant outcomes?

机构信息

Division of Nephrology, University of California, San Francisco, USA.

出版信息

Am J Nephrol. 2012;35(2):191-7. doi: 10.1159/000335935. Epub 2012 Jan 27.

DOI:10.1159/000335935
PMID:22286715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3326277/
Abstract

BACKGROUND

Awareness of chronic kidney disease (CKD) is low. Efforts are underway to increase recognition of CKD among patients, assuming that such an increase will lead to better outcomes through greater adherence to proven therapies. Few studies have tested this assumption.

METHODS

CKD awareness, defined by a 'yes' answer to 'Have you ever been told by a healthcare provider you have weak or failing kidneys?', was assessed among 2,404 adults with CKD stages 1-4, who participated in the 2003-2008 National Health and Nutrition Examination Surveys. Odds of blood pressure (BP) control, self-reported use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), and glycemic control, were determined among those aware vs. unaware of their CKD.

RESULTS

Optimal BP control, ACEI/ARB use and glycemic control were low in the US adult population with CKD, although there was a recent increase in attainment of guideline-concordant BP control. Odds of BP control and ACEI/ARB use were not different among individuals aware of their CKD compared to those unaware (adjusted odds ratio (AOR) 0.91; 95% CI 0.52-1.58 and AOR 0.75; 0.44-1.30, respectively). CKD awareness among diabetic participants was not associated with glycemic control (AOR 0.41; 95% CI 0.14-1.18).

CONCLUSION

Awareness of CKD is not associated with more optimal BP control, ACEI/ARB use or glycemic control. Future efforts in this area should further explore the measurement of CKD awareness and behaviors associated with CKD awareness.

摘要

背景

慢性肾脏病(CKD)的知晓率较低。目前正在努力提高患者对 CKD 的认识,假设这种认识的提高将通过提高对已证实疗法的依从性而带来更好的结果。但很少有研究检验过这一假设。

方法

在参加了 2003-2008 年全国健康和营养调查的 2404 名 CKD 1-4 期患者中,通过“您是否曾被医疗保健提供者告知您的肾脏功能较弱或衰竭?”这一问题来评估 CKD 知晓率。在知晓与不知晓 CKD 的患者中,比较了血压(BP)控制、报告的血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)使用情况以及血糖控制的可能性。

结果

尽管最近达到了符合指南的 BP 控制标准,但美国 CKD 成年人群的理想 BP 控制、ACEI/ARB 使用和血糖控制率仍较低。与不知晓 CKD 的患者相比,知晓 CKD 的患者的 BP 控制和 ACEI/ARB 使用的可能性并无差异(校正比值比(AOR)0.91;95%置信区间(CI)0.52-1.58 和 AOR 0.75;0.44-1.30)。糖尿病患者的 CKD 知晓率与血糖控制无关(AOR 0.41;95% CI 0.14-1.18)。

结论

CKD 知晓率与更理想的 BP 控制、ACEI/ARB 使用或血糖控制无关。未来在这一领域的努力应进一步探讨 CKD 知晓率的衡量方法以及与 CKD 知晓率相关的行为。